Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

The Lancet. Oncology·2026
Same author

Neoadjuvant stereotactic body radiation therapy plus immune therapy favorably remodels the hepatocellular carcinoma tumor microenvironment.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Nature·2026
Same author

Early detection of aberrant cell fate and repair using circulating progenitor cells in patients with heterotopic ossification.

Nature communications·2026

Related Experiment Video

Updated: Oct 6, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition.

Nezihi Murat Karabacak1,2, Yu Zheng3, Taronish D Dubash3

  • 1Center for Engineering in Medicine and Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Cancer Research
|January 20, 2022
PubMed
Summary

Single-cell proteomics reveals how kinase signaling heterogeneity drives varied cancer drug responses. Understanding these differences in tumor cells and sites is key to improving targeted therapy effectiveness.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.8K

Related Experiment Videos

Last Updated: Oct 6, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Proteomics

Background:

  • Cancer therapy responses vary significantly due to tumor heterogeneity.
  • Limited sensitivity of current methods hinders understanding of cell signaling within tumors.
  • Inter- and intratumor heterogeneity impacts therapeutic outcomes.

Purpose of the Study:

  • To investigate kinase activity evolution in different tumor compartments using single-cell mass cytometry.
  • To characterize the impact of microenvironment and cell state on drug sensitivity.
  • To define a new paradigm for understanding drug responses to kinase inhibitors.

Main Methods:

  • Applied single-cell mass cytometry with a 26-antibody panel.
  • Utilized PTEN-deleted orthotopic prostate cancer xenograft models.
  • Analyzed kinase activities in primary tumors, metastases, and circulating tumor cells (CTCs).

Main Results:

  • Bone metastases showed elevated PI3K/mTOR signaling and c-MET overexpression compared to other sites.
  • Suppression of c-MET inhibited bone tumor growth.
  • Epithelial (EpCAM-high) and mesenchymal (EpCAM-low) cell populations exhibited distinct kinase activities and drug sensitivities.
  • Mesenchymal CTCs in patients mirrored findings in xenograft models.

Conclusions:

  • Microenvironment and cell state-dependent kinase activation create significant heterogeneity in drug sensitivity.
  • Single-cell proteomics offers crucial insights into differential responses to targeted therapies.
  • This study defines a new framework for understanding cancer drug responses across diverse tumor populations and sites.